351 results on '"Iannitto, Emilio"'
Search Results
2. Splenic Marginal Zone Lymphoma
3. Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study
4. Pseudotemporal ordering of spatial lymphoid tissue microenvironment profiles trails Unclassified DLBCL at the periphery of the follicle
5. Bone marrow stroma CD40 expression correlates with inflammatory mast cell infiltration and disease progression in splenic marginal zone lymphoma
6. Methodological Issues in the Baffling Relationship Between Hepatitis C Virus and Non Hodgkin’s Lymphomas
7. How I diagnose and treat splenic lymphomas
8. Absolute Monocyte Count and Lymphocyte-Monocyte Ratio Predict Outcome in Nodular Sclerosis Hodgkin Lymphoma: Evaluation Based on Data From 1450 Patients
9. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin’s lymphoma patients: A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL)
10. Description of a Clinical Score to Identify PMBL Patients at High Risk of Early-Failure after Rituximab Doxorubicin Back-Bone Chemoimmunotherapy. a FIL Real-World Study
11. Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory/relapsing B-cell lymphoma
12. Advanced mast cell disease: an Italian Hematological Multicenter experience
13. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
14. Screening for Celiac Disease in Non-Hodgkin's Lymphoma Patients: A Serum Anti-Transglutaminase–Based Approach
15. Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need
16. Total body computed tomography scan in the initial work-up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O-CLL1-GISL study
17. ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
18. Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma
19. Bone marrow biopsy in hemophagocytic syndrome
20. Splenic marginal zone lymphoma: a prognostic model for clinical use
21. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study
22. Long‐term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials
23. Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real‐world study
24. Sideropenic Anemia and Celiac Disease (One Study, Two Points of View)
25. Gamma-delta T-cell lymphomas
26. Evaluating the risk of hepatitis B reactivation in patients with haematological malignancies: is the serum hepatitis B virus profile reliable?
27. Response-Guided ABVD Chemotherapy plus Involved-Field Radiation Therapy for Intermediate-Stage Hodgkin Lymphoma in the Pre-Positron Emission Tomography Era: A Gruppo Italiano Studio Linfomi (GISL) Prospective Trial
28. Methodological Issues in the Baffling Relationship Between Hepatitis C Virus and Non Hodgkin’s Lymphomas
29. Use of intrapleural bortezomib in myelomatous pleural effusion
30. Reply to Pich et al.: intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study
31. Assessment of the frequency of additional cancers in patients with splenic marginal zone lymphoma
32. Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes
33. Hepatitis B virus reactivation and alemtuzumab therapy
34. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study
35. The clinical value of tumor burden at diagnosis in Hodgkin lymphoma
36. PROGNOSTIC FEATURES OF SPLENIC LYMPHOMA WITH VILLOUS LYMPHOCYTES
37. ARE BLOOD DONORS AN ADEQUATE CONTROL GROUP TO ASCERTAIN HCV PREVALENCE IN NON-HODGKINʼS LYMPHOMA PATIENTS
38. Hepatosplenic γδ T-cell lymphoma: complete response induced by treatment with pentostatin
39. Potential strategies for the treatment of plasma exchange-resistant thrombotic thrombocytopenic purpura
40. Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study
41. Splenic marginal zone lymphoma
42. Continuous intravenous infusion of dipyridamole as adjunctive therapy in the treatment of thrombotic thrombocytopenic purpura
43. Comparison of prognostic models in patients with advanced Hodgkin disease: promising results from integration of the best three systems
44. Splenectomy influences bone marrow infiltrationtg in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes
45. A rapidly progressive motor neuron disease associated to a natural killer cells leukaemia
46. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study
47. Paroxysmal nocturnal hemoglobinuria: When delay in diagnosis and long therapy occurs
48. Re: “Splenic marginal zone B-cell lymphoma associated with primary Sjögren’s syndrome”
49. Two Cases of Q-Fever in Hairy Cell Leukemia
50. Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.